First Tracks Biotherapeutics

A large cash balance relative to liabilities gives management the optionality to fund near‑term clinical milestones without immediate dilutive financing, preserving upside if readouts are positive. If cash funds meaningful readouts, positive results can re‑rate the equity; if not, the company will likely raise capital and dilute existing holders.

A clean balance sheet (low liabilities vs cash) reduces short‑term solvency risk and increases the chance management can pursue value‑creating options like selective partnering or milestone‑driven spend. Low leverage buys time for clinical programs to mature without the pressure of immediate debt service or covenant‑driven exits; loss of that cushion forces urgent capital raises and strategic concessions.

If clinical progress stalls or costs exceed expectations, the company will likely raise equity, making dilution the primary pathway by which intrinsic value is transferred away from existing shareholders. Dilution at a lower post‑money valuation would materially reduce per‑share value even if the underlying programs retain some value; avoiding dilutive financings preserves optionality for current holders.